Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

41.59USD
20 May 2019
Change (% chg)

$0.12 (+0.29%)
Prev Close
$41.47
Open
$41.40
Day's High
$41.71
Day's Low
$41.28
Volume
23,009,069
Avg. Vol
24,417,480
52-wk High
$46.47
52-wk Low
$35.32

Select another date:

Wed, May 15 2019

Photo

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

UPDATE 1-Pfizer's atopic dermatitis treatment meets goals in late-stage study

May 15 Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday.

Pfizer's dermatitis treatment meets main goals of late-stage study

May 15 Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday.

GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

UPDATE 1-GSK-Pfizer deal gets approval from Australia's anti-trust watchdog

May 9 GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business will not lesson competition in Australia, the country's anti-trust regulator said on Thursday as it approved the deal.

Australia's anti-trust watchdog gives go-ahead for GSK-Pfizer consumer healthcare deal

May 9 Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business.

Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

UPDATE 2-Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK, May 6 The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Pfizer gets U.S. approval for $225,000 a year heart drug

NEW YORK, May 6 The U.S. Food and Drug Administration on Monday approved Pfizer Inc's drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.

Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Select another date: